Review Article
Efficacy and Safety of Topical Corticosteroids for Management of Oral Chronic Graft versus Host Disease
Table 2
The evidence table including study design, interventions, outcomes, level of evidence, and grade of recommendation.
| Study | Quality assessment | Number of patients | Drug properties | Clinical response (efficacy) | Safety % | Level | Grade | Drug | Conc. | Dose | Average time for best results (D) | Average mOMRS reduction (%) | Patients with mOMRS improvement (%) | VAS red. (%) | Side effects % | mL | t/d |
| Clobetasol | Noce et al. [7] | 1b | A | 14 | Oral rinse | 0.5 | 5 | 3 | 28 | 50 | 85 | 44.6 | 7 |
| Dexamethasone | Noce et al. [7] | 1b | A | 18 | Oral rinse | 0.01 | 5 | 3 | 28 | 50 | 33 | 29.7 | 5.5 | Park et al. [8] | 2b | B | 24 | Oral rinse | 0.01 | 10 | 3-4 | 28 | 27.2 | 29.1 | 28.5 | 16.6 | Wolff et al. [9] | 4 | C | 16 | Oral rinse | 0.01 | NR | NR | 28 | NR | 68.7 | NR | NR |
| Budesonide | Park et al. [8] | 2b | B | 26 | Oral rinse | 0.03 | 5–10 | 3–6 | 28 | 50 | 53.8 | 37.5 | 19 | Elad et al. [10] | 2b | B | 18 | Oral rinse | 0.03 | 10 | 2-3 | 45.5 | 70 | 70 | 70 | 50 | Sari et al. [9] | 4 | C | 12 | Oral rinse | 0.03 | 10 | 3 | 28 | 66.6 | 83.3 | 54.4 | 16.6 | Elad et al. [12] | 4 | C | 12 | Oral rinse | 0.06 | 5 | 2-3 | 54 | UC | 100 | UC | 8 |
|
|
RCT: randomized clinical trial, pro-cohort: prospective cohort, Retro. Cohort: retrospective cohort, UC: unclear, and NR: not reported.
|